← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Hb Therapeutics, Inc.
Indianapolis, IN
$2,299,119
Total funding
2
Grants
Funding over time
peak $1M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,299,119 · 2
By mechanism
R44$1,999,119 · 1
R43$300,000 · 1
Investigators at Hb Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$1,019,583
R44 · FY2022 · CA
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$979,536
R44 · FY2023 · CA
Development of Small Molecule SUMO1 Inhibitors for Treatment of Glioblastoma$300,000
R43 · FY2018 · CA